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1. Introduction
===============

Numerous cases of neurodegenerative and multisystemic disease of unknown origin have been described in juvenile and adult cheetahs in the European Endangered Species Program (EEP; [@BIB30], [@BIB31]). This neurodegenerative disease characterised by upper motor neurone lesions, progressive ataxia, hind limb paresis and paralysis, and bilateral symmetric myelin degeneration associated with axonal degeneration of the spinal cord is described as cheetah myelopathy [@BIB31]. Despite extensive postmortem examinations, the aetiology of this neurodegeneration and of the possibly high disease prevalence in cheetahs remains unclear [@BIB13], [@BIB31]. Neurodegenerative diseases of unknown cause have also been observed in the South African and North American captive cheetah populations [@BIB18], in snow leopard cubs [@BIB22] and in domestic animal species [@BIB3], [@BIB20], [@BIB28].

Besides idiopathic origin, the major causes for neurodegeneration include environmental, pathogenic and genetic factors [@BIB12]. The genetic factors include nuclear and mitochondrial DNA (mtDNA) defects or derangements in the interaction of the two genomes. Nuclear DNA defects as such cause a large group of neurodegenerative diseases [@BIB12]. Beyond that, mutated nuclear gene products targeted to mitochondria can affect the organellar function and replication and thus can impair almost any aspect of cellular function and oxidative energy metabolism [@BIB24]. The mitochondria harbour the oxidative respiratory system (OXPHOS), and therefore disorders arising from defects in the nucleus and mitochondria encoded subunits of OXPHOS are also referred to as 'mitochondrial' diseases. Since the discovery of these mitochondrial diseases, more than 100 point mutations and innumerable mtDNA rearrangements have been identified as cause for various types of progressive neurodegenerative and multisystemic diseases [@BIB7].

The neurodegenerative disease of cheetahs shows symptoms comparable to human mitochondrial diseases, e.g., complex I (NADH dehydrogenase) deficiencies, myoclonic epilepsy with ragged red fibres (MERRF), mitochondrial encephalomyopathy, lactic acidosis and strokelike episodes (MELAS) and neuropathy, ataxia, retinitis pigmentosa (NARP). In addition, ataxia in humans has been associated with large-scale deletions in the mtDNA, e.g., the 'common deletion' of 4977 bp representing over 50% of deletions in the human mtDNA [@BIB17].

In this study we addressed the issue of a possible extrachromosomal genetic cause for the phenotype of neurodegenerative disease in the EEP cheetah population. Due to the progressive course of this disease resulting in the exclusion of myelopathic animals from breeding programs, we were not able to demonstrate the presence or absence of Mendelian inheritance for this trait. In view of the phenotypic comparability of the progressive neurodegeneration in the cheetah and human mitochondrial diseases, we investigated whether mutations in the cheetah mtDNA were associated with the myelopathic phenotype. For this purpose we determined the complete mitochondrial genome of two myelopathic and two non-myelopathic cheetahs and selected coding regions as candidate genes for analysis including homo- and heteroplasmic base substitutions and deletions.

2. Materials and methods
========================

2.1. Biological material
------------------------

The international studbook numbers [@BIB15] of the cheetahs included in this study, dates of birth and death, information on the animal origin, type of sample specimen and the occurrence of the myelopathic phenotype are included in [Table 1](#TBL1){ref-type="table"} .Table 1Details on the *A. jubatus jubatus* individualsHaplotypeCheetah no.Sample specimenMyelopathyStudbook numberOriginDates of birth and deathCause of deathI1muscle, liver CNS, blood+4050F122.03.98/31.10.00EI2muscle, liver CNS, blood+4237F103.06.00/31.10.00EI3ablood[a](#TBLFN1){ref-type="table-fn"}−3671A127.10.96/05.03.02EI3bmuscle+3671A127.10.96/05.03.02EI4blood−3672A127.10.96/aliveNAI5liver+4353F222.03.01/29.04.01EI6liver+4508F217.10.01/01.03.02EI7liver−4509F217.10.01/18.12.01aortic ruptureI8liver−4510F217.10.01/17.12.01aortic aneurysmI9muscle+4513F217.10.01/01.03.02EI10lung−1463F11983/07.11.00senileI11muscle−1755F11986/06.06.02senileI12blood−3285F120.09.94/aliveNAI13blood−3722F118.12.96/aliveNAI14muscle+4058F114.04.99/07.06.02EI15liver+4059F114.04.99/07.06.02EI16blood−4060F114.04.99/aliveNAI17blood−4487F118.08.01/aliveNAI18blood−not reg; ID 3383F12002/aliveNAI19blood+1775A114.10.88/29.05.02EI20blood+1921A118.05.89/29.05.02EI21CNS+3619A125.05.96/11.11.96EI22CNS+3799A119.09.97/24.08.98EI23muscle−3147A305.11.93/23.09.02renal failureI24CNS (PET)+2819A11987/05.06.99EI25CNS (PET)+3800A119.09.97/24.11.98EI26CNS (PET)+4363UAE1987/01.06.96EI27CNS (PET)+not reg; ID Fota 1IRE01.06.97/21.08.97EII28muscle+not reg; ID DoumaF301.06.02/11.09.02EII29CNS+1976D17.12.86/21.04.98EIII30CNS−not reg; ID S/1571A21997/1997mega-colon[^1][^2]

2.2. DNA isolation
------------------

For the determination of the *A. jubatus* mtDNA reference sequence, DNA was isolated from mitochondria-enriched tissue fractions to exclude amplification from nuclear mitochondrial pseudogenes [@BIB29]. Native tissue samples (10 g) from liver, right muscle quadriceps, central nervous system and cardiac muscle were taken immediately after euthanization and transported to the laboratory in ice-cold buffer containing 0.25 M sucrose, 1 mM EDTA and 10 mM Tris--HCl (pH 7.4). The mitochondrial fraction was obtained by differential centrifugation [@BIB10] and used for mtDNA isolation.

Total cellular DNA was extracted from blood and native or paraffin embedded tissue samples. Paraffin samples were cut from 2×2-cm blocks into 5--10-μm sections and extracted with 1-ml xylene. DNA isolations were carried out using the NucleoSpin® Blood or Tissue kits (Machery & Nagel, Dueren, Germany) resulting in 60 μl containing ≤20-μg DNA.

2.3. PCR and sequencing
-----------------------

Amplification primers were designed with Primer Express (Applied Biosystems, Vienna, Austria) using cheetah sequences for *MTATP8*, *MTND5* and *MT16SrRNA* (GenBank accession nos. [AF241817](AF241817), [AF241816](AF241816) and [AF141815](AF141815)) and conserved regions determined by aligning mitochondrial genes of related felid species (*Felis catus*, *Panthera leo*, *P. tigris*, *P. pardus*, *P. onca*; GenBank accession nos. [U20753](U20753), [AF006458](AF006458), [AF006460](AF006460), [AF006444](AF006444) and [AF006442](AF006442)).

Control region (CR) sequences, excluding the two repeat elements RS2 [@BIB11] and RS3 [@BIB14], were applied for haplotype classification. Five partially overlapping amplicons generated with the primer pairs CR1f (16,252--16,273)/CR1r (16,503--16,473), CR2f (16,787--16,810)/CR2r (17,029--17,008), CR3f (16,961--16,985)/CR3r (187--166), CR4f (35--52)/CR4r (236--218) and CR5f (644--662)/CR5r (895--877) and fitting the reduced maximum amplification length due to formalin fixation before paraffin embedding, were sequenced.

The analysis of the mitochondrial leucine UUR, serine UCN and lysine tRNAs and the partial amplification of the complexes I and V were performed with the primer pairs LEUf (3366--3387)/LEUr (3673--3654), SERf (7512--7533)/SERr (7860--7843), LYSf (8401--8425)/LYSr (8720--8696), N4Lf (10,933--10,954)/N4Lr (11,334--11,316), N5~1~f (14,032--14,052)/N5~1~r (14,295--14,275), N5~2~f (14,077--14,100)/N5~2~r (14,357--14,335), A8f (8639--8662)/A8r (8937--8915), A6~1~f (9204--9225)/A6~1~r (9552--9531) and A6~2~f (9466--9490)/A6~2~r (9875--9856). The numbering (5′--3′) is according to the GenBank accession no. [AF344830](AF344830).

PCR was performed in a 25-μl volume containing 60 mM Tris--HCl (pH 8.5), 15 mM (NH4)~2~SO~4~, 1.5 mM MgCl~2~, 0.2 mM of each dNTP, 600 nM of each primer, 1.25 U *Taq* polymerase (Invitrogen, Lofer, Austria), and 1.5-μl (10--30 μg) DNA template. Conditions for the amplification of the approximately 700-bp PCR fragments on the RoboCycler® (Stratagene, Amsterdam, Holland) were: 5 min/95 °C, 1 min/50 to 59 °C, 3 min/72 °C and 38 cycles of 30 s/95 °C, 45 s/50 to 59 °C, 80 s/72 °C. PCR products were purified with a binding buffer containing 7 M Guanidinium--HCl and 200 mM MES (pH 5.6) and MultiScreen®-FB Opaque Plates (Millipore, Vienna, Austria), and sequenced with the ABI PRISM® BigDye Terminators v3.0 Cycle Sequencing Kit (Applied Biosystems). The amplification primers were applied for PCR product sequencing of both strands. Unincorporated dyes were removed with the Sephadex™ G-50 Superfine System (Sigma-Aldrich, Vienna, Austria) and MultiScreen®-HV Clear Plates (Millipore). Capillary electrophoresis of the sequencing reactions was performed on the MegaBACE 1000 automated DNA sequencer (Amersham, Buckinghamshire, Great Britain). Electropherograms were reevaluated by visual inspection using the computer programs Sequence Navigator Version 1.0.1 and Autoassambler Version 2.1 (Applied Biosystems). Numbering and determination of the gene boundaries within the cheetah mtDNA were performed on the basis of the *F. catus* mtDNA (GenBank accession no. [NC_001700](NC_001700)). The classification of amino-acid substitutions was performed as described [@BIB6].

2.4. Amplification refractory mutation system (ARMS) allele-specific real-time PCR
----------------------------------------------------------------------------------

ARMS allele-specific quantitative real-time PCR [@BIB26] was used to quantify the relative amount of the heteroplasmic single nucleotide polymorphism (SNP). PCR assays of 25 μl contained 60 mM Tris--HCl (pH 8.5), 15 mM (NH4)~2~SO~4~, 0.2 mM dATP, dCTP, dGTP and 0.4 mM dUTP, 300 nM of each primer, 150 nM of the fluorogenic probe, 1.25 units of *Taq* polymerase, 3.5 mM MgCl~2~ and 1.5-μl template DNA. Real-time PCR was performed with the ABI PRISM™ Sequencing Detection System 7900 (Applied Biosystems). The threshold cycle (*C* ~T~) values, i.e., the *C* ~T~ was defined as the cycle at which an amplification plot reached a significant threshold, were determined using the Sequence Detector 2.1 software (Applied Biosystems). The allele-specific ARMS [@BIB19] reverse primer was designed to discriminate between the alleles G and A at nt 14,175 (GenBank accession no. [AF344830](AF344830)). To further inhibit amplification of the nontarget allele, a mismatch at position 3 from the 3′ end of the primer was arbitrarily introduced. This substitution generating a mismatch with both alleles at this bi-allelic site is printed in capital letter: ARMS (gag ttt taa gtt ttt ggc Aac, 14,175--14,196). The oligonucleotides TM1 (14,103--14,122) and TM2 (14,169--14,149) were used to quantify the total amount of mtDNA. The hydrolysis probe TMP (14,243--14,267) was labelled at the 5′ end with 6-carboxyfluorescein (6FAM™) and at the 3′ end with 6-carboxytetramethylrhodamine (TAMRA™). ARMS allele-specific real-time PCR was performed with 5 min at 95 °C, 40 cycles for 15 s at 95 °C, 30 s at 52 °C and 30 s at 72 °C. To test the reliability of the PCR, each sample was amplified in duplicates with a standard deviation of threshold cycle (*C* ~T~) values not exceeding 0.5. Samples with *C* ~T~ values \>32 were amplified in quadruplicates and the highest and lowest values were excluded. Each experiment included a standard curve (regression coefficient R^2^\>0.991), a non-template control and a nontarget amplification control (NTAC). The NTAC consisted of the synthetic oligonucleotide (14,103--14,195; MWG Biotech, Ebersberg, Germany) including the nontarget allele A at nt 14,175 and carrier salmon sperm DNA (Invitrogen). The percentage of the G allele at 14,175 was determined by the "Comparative *C* ~T~ method" (ABI PRISM 7700 sequence detection system, Applied Biosystems, 1997) using the equation: Heteroplasmy=100%/(1+*E*)^ΔΔ*C*~T~^, where the efficiency (*E*)=10^−1/*s*^−1. The slope (*s*) being a measure for the efficiency of the PCR reaction is determined by the standard curve *y*=*sx*+*b*. ARMS allele-specific real-time PCR targeted the G-allele at 14,175. Assuming a bi-allelic locus, we calculated for the percentage of the mutant allele A: 100%−allele G. Statistical analyses were performed with SPSS Version 9.0.1 (SPSS, Chicago, USA).

2.5. Screening for mtDNA deletions
----------------------------------

As deletions often occur within direct repeats of mtDNA sequences [@BIB17], the complete mitochondrial genomes of cheetahs \#1--4 were analysed with the Repeat Masker Server Version 07.07.02 [http://ftp.genome.washington.edu/](http://www.ftp.genome.washington.edu/)).

Long-range PCR to screen for large-scale mtDNA deletions was performed with the primer pair LR1 (16,183--16,206)/LR2 (15,728--15,708) and the TripleMaster® PCR System (Eppendorf, Wesseling-Berzdorf, Germany). Following DNA denaturation for 3 min at 93 °C, amplification was performed for 27 cycles (15 s/93 °C, 20 s/56 °C, 17 min/68 °C). During the last 17 cycles the extension time was increased by 20 s per cycle. PCR products were run on a 0.7% agarose gel at 3 V/cm for 18 h.

2.6. GenBank accession numbers
------------------------------

Complete mtDNA sequences ([AF344830](AF344830), cheetah \#1; [AY463959](AY463959), cheetah \#2), partial sequences of the mitochondrial control region ( [AY463960](AY463960), cheetah \#18; [AY463961](AY463961), cheetah \#29; [AY463962](AY463962), cheetah \#30) and partial sequences of polymorphic mitochondrial genes ( [AY486335](AY486335), cheetah \#29; [AY486336](AY486336), cheetah \#30) were submitted to the GenBank.

3. Results
==========

3.1. Analysis of the complete mtDNA sequence and mtDNA haplotyping of *A. jubatus*
----------------------------------------------------------------------------------

Relevant biological data of the cheetahs (*n*=30) analysed are presented in [Table 1](#TBL1){ref-type="table"}. The mitochondria-enriched liver fractions from myelopathic cheetahs \#1 and 2 and blood samples from non-myelopathic animals \#3a and 4 were used to determine a reference mitochondrial genome. In the course of the study, cheetah \#3a developed symptoms of neurodegenerative disease and was therefore euthanized [(Table 1)](#TBL1){ref-type="table"}. The cross-check of muscle tissue from the euthanized animal (termed \#3b) showed no differences to the sequence determined from the blood sample.

The classification of the cheetahs into haplotypes I to III (*n*=27, *n*=2 and *n*=1, respectively) was based on SNPs of mitochondrial control region sequences [(Table 2)](#TBL2){ref-type="table"} and pedigree analysis [(Fig. 1)](#FIG1){ref-type="fig"} . Haplotype I included 25 related and two unrelated cheetahs, whereas haplotypes II and III included only individuals with unknown parental origin. [Fig. 1](#FIG1){ref-type="fig"} illustrates the pedigree of the related haplotype I animals and the transmission of the myelopathic phenotype; the presence and absence of myelopathy were histopathologically confirmed. Mendelian inheritance of the myelopathy could not be demonstrated because of the progressive aetiopathology and insufficient sample size.Table 2Haplotype classification of the 30 cheetahsHaplotypeCheetah no.mtDNA regionSubstitution (amino acid change)I\#1--27CRwild type\#1, 2, 5--12, 14--18, 24--27MTND5G14175G/A (V507M)[a](#TBLFN2){ref-type="table-fn"}II\#28, 29CRG16,828AMTND5T14,176C (V507A)[b](#TBLFN3){ref-type="table-fn"}III\#30CRG16,828ACRT159CCRA203GMTND4LG11021A (no)[^3][^4]Fig. 1Pedigree illustrating the relationship of cheetahs \#1 to 4 used for the determination of the mitochondrial genome, the transmission of the myelopathic phenotype and the heteroplasmy *G14,175A*. Cheetah \#3 is presented with the myelopathic phenotype after developing neurodegenerative symptoms in the course of the study. Square: male; circle: female; white: health status unknown; black: myelopathic; grey: non-myelopathic; w: wild-born (Namibia); HP−: homoplasmic at 14,175 (wild-type, *14,175G*); HP+: heteroplasmic at 14,175 (*G14,175A*); n.a.: not analysed (no material available).

The *A. jubatus* mtDNA is 17,047-bp long and is composed of 33.1% A, 25.8% C, 13.6% G and 27.5% T, respectively. The numbering and determination of the gene boundaries within the mitochondrial genome of cheetah \#1 [(Table 3)](#TBL3){ref-type="table"} were performed on the basis of the *F. catus* mtDNA (GenBank accession no. [NC_001700](NC_001700)). Similar to other mammals, the *A. jubatus* mtDNA is composed of 13 protein-coding genes resembled by structural open reading frames, 22 tRNAs, the 12S- and 16S-rRNA and the regulatory control region. Sequence comparisons to the cat and human (GenBank accession nos. [NC_001700](NC_001700) and [J01415](J01415)) showed an overall homology of 91% and 80%, respectively. Protein translation is generally initiated by the start codon ATG (Met) except for *MTND2* which is initiated at ATT (Ile). The cheetah mtDNA lacks complete termination codons in the genes *MTND1*, *MTND2*, *MTCO3*, *MTND3* and *MTND4*. As in transcripts of human peptide-coding mitochondrial genes, *MTND1*, *MTND2*, *MTCO3* and *MTND3* contain a stop codon created by posttranscriptional polyadenylation. Therefore, most stop codons in the cheetah mtDNA are TAA. Furthermore, coding sequences overlap between the *MTATP8* and *MTATP6*, the *MTND4* and *MTND4L*, and the *MTND5* and *MTND6* genes, respectively. The CR contains the RS2 and RS3 repeat units as described in other cheetah subspecies [@BIB11]. The light strand encodes the *MTND6* gene and the tRNAs glutamine, alanine, aspargine, cysteine, tyrosine, serine UCN, glutamic acid and proline. The origin of light strand replication (OLR; 6074 to 6105) contains a poly-A stretch; A is repeated nine times in cheetah \#4 and 10 times in animals \#1--3.Table 3The composition of the complete mitochondrial genome of the cheetahGeneNucleotide positionNumberSizeCodon5′ intervening spacerFromTo(bp)[a](#TBLFN4){ref-type="table-fn"}StartStop[b](#TBLFN5){ref-type="table-fn"}tRNA^Phe^89396270rRNA-12S9631922960tRNA^Val^1923199068rRNA-16S199135621572tRNA^Leu\ (UUR)^3563363775ACND136404596957ATGTA--[b](#TBLFN5){ref-type="table-fn"}tRNA^Ile^4596466469tRNA^Gln^4662473574 (L)AtRNA^Met^4737480569ND2480658471042ATTT--[b](#TBLFN5){ref-type="table-fn"}tRNA^Trp^5848591568CATACCAAACTGCCTtRNA^Ala^5931599969 (L)tRNA^Asn^6001607373 (L)RepOrigin OLR6074610532tRNA^Cys^6106617166 (L)tRNA^Tyr^6172623867 (L)TCO1624077841545ATGTAAtRNA^Ser\ (UCN)^7783785270 (L)TTAAtRNA^Asp^7857792569CO279258608684ATGTAAATTtRNA^Lys^8612867968TATP886818884204ATGTAAATP688429522681ATGTAACO3952210,305784ATGT--[b](#TBLFN5){ref-type="table-fn"}tRNA^Gly^10,30610,37469ND310,37510,721347ATATA--[b](#TBLFN5){ref-type="table-fn"}tRNA^Arg^10,72210,79069ND4L10,79111,087297ATGTAAND411,08112,4581378ATGT--[b](#TBLFN5){ref-type="table-fn"}tRNA^His^12,45912,52769tRNA^Ser\ (AGY)^12,52812,58659tRNA^Leu\ (CUN)^12,58712,65670ND512,65714,4771821ATATAAND614,46114,988528 (L)ATGTAAtRNA^Glu^14,98915,05769 (L)CytB15,06116,2001140ATGAGATTAtRNA^Thr^16,20116,27069tRNA^Pro^16,27116,33767 (L)CR16,3388921602[^5][^6]

3.2. Analysis of genetic variation in the cheetah mtDNA
-------------------------------------------------------

Cheetah mtDNA regions were selected for further analysis according to human mtDNA regions associated with mitochondrial diseases. The seven mitochondrially encoded complex I subunits of three myelopathic cheetahs (\#1, 2 and 3b) were compared with those of three nondiseased control animals (\#3a, 4 and 23). Cheetahs \#3, 4 and 23 were genetically invariant across these seven genes. In contrast, cheetahs \#1 and 2 were polymorphic in the *MTND5* gene. The SNP was heteroplasmic and consisted of a G to A transition at position 14,175 (*G14,175A*) leading to a nonconservative amino acid change valine to methionine (*V507M*). This heteroplasmy was detected in 17 other animals of haplotype I. The individual levels of the heteroplasmy were quantified by ARMS allele-specific real-time PCR and are given in [Fig. 2](#FIG2){ref-type="fig"} . The heteroplasmic animals represented both clinical phenotypes (*n*=11 myelopathic, *n*=8 non-myelopathic), and neither the occurrence (chi-square test: *p*=0.551) nor the percentage (*p*=0.440) of heteroplasmy was significantly associated with the neurodegenerative disease in the examined cheetahs. Furthermore, no significant correlation between the heteroplasmy and the different tissue samples was found (Kruskal--Wallis test: *p*=0.823). The comparison of the heteroplasmic level with the age of the individual animals resulted in a nonsignificant negative correlation (Spearman Rho-test: −0.419, *p*=0.301).Fig. 2Quantification of the heteroplasmic level *G14,175A*. The heteroplasmic levels range from 32% to 81% in myelopathic animals (given in black) and from 29% to 76% in cheetahs without confirmed myelopathy (given in grey). Due to the limited availability of postmitotic tissue samples, the issue of an intraindividual difference in the heteroplasmic level of postmitotic versus mitotic tissues could not be addressed (e.g., cheetah \#1: muscle (32.1%±4.5) and CNS (64.4%±0.9) versus liver (46.5%±9.1) and blood (40.7%±9.4); cheetah \#2: muscle (61.2%±7.7) and CNS (31.9%±2.2) versus liver (19.6%±6.6) and blood (23.9%±2.1)).

Complex I partial sequence analysis of all cheetahs revealed another homoplasmic polymorphic variant in the *MTND5* gene (*T14,176C*) of cheetahs \#28, 29 leading to the conservative amino acid change valine to alanine in the codon 507. The conservative and nonconservative amino-acid exchanges at the codon 507 were not significantly correlated with the occurrence of the myelopathy (chi-square test: *p*=0.571). An additional SNP in the *MTND4L* gene of cheetah \#30 without an amino acid substitution was found [(Table 2)](#TBL2){ref-type="table"}.

As the clinical symptoms of myelopathic cheetahs could be compared with the human mitochondrial diseases MERRF, MELAS and NARP [@BIB7], the mtDNA regions associated with these diseases were screened in all animals. No genetic variation for the tRNA^Leu(UUR)^, tRNA^Ser(UCN)^, tRNA^Lys^ and in the partial sequences (8680--8850 and 9280--9800) of the complex V genes was found (data not shown).

Large-scale deletions in the human mtDNA have been identified as a cause for several mitochondrial diseases and most deletion breakpoints occur within direct repeat sequences [@BIB17]. The mtDNA of the cheetah includes three direct repeats of 4, 5 and 6 bp in length (3562--3565/3641--3644; 4660--4664/4731--4735; 7782--7787/7854--7859). As demonstrated in [Fig. 3](#FIG3){ref-type="fig"} , the amplification products of the approximately 16.5-kb mtDNA fragments from three myelopathic (\#1, 5, and 28) and three non-myelopathic cheetahs (\#7, 8, and 18) did not show any additional shorter bands indicating the absence of large-scale deletions.Fig. 3Deletion screening via long range PCR. M~p~=1-kb Plus Ladder (Invitrogen); M~λ~=Lambda Mix Marker, 19 (MBI Fermentas, St. Leon-Rot, Germany).

4. Discussion
=============

This study established the complete sequence of the mitochondrial genome of *A. jubatus* and performed analysis of polymorphic sites in coding regions of animals with and without myelopathy. Myelopathy in the cheetah is a progressive neurodegenerative disease of the spinal cord, which affects cheetahs in captivity in Europe and the Middle East and has an unknown aetiology [@BIB13], [@BIB31]. In view of the phenotypic similarities of the diseases in the EEP cheetah population with human mtDNA-associated diseases, the cheetah mitochondrial genome was analysed to reveal a possible extrachromosomal genetic basis for the myelopathy.

Generally, the cheetah is unusual among Felidae in exhibiting high genetic uniformity at a variety of genetic loci including the mtDNA. This is caused by a population bottleneck about 12,000 years ago [@BIB8]. The cheetah mtDNA shows a high sequence similarity (91%) to the domestic cat [@BIB14] and possesses several features also observed in other mammalian species [@BIB2], [@BIB32]. Due to an accumulation of repeat sequences and AT-rich intergenic spacers, the length of non-coding and intergenic regions can vary considerably within a genus [@BIB4], a fact also observed in the CR and OLR of the cheetah.

Based on pedigree information and polymorphisms in the CR, all animals included in this study were classified into three haplotypes and the majority of the cheetahs were considered to be related. Due to the progressive course of the neurodegenerative disease, a heritability for this trait could not be shown. The maternal transmission of the heteroplasmy observed at the site 14,175 could be demonstrated for the related haplotype I animals, apart from one cheetah of wild-born parental origin. In general, mtDNA is maternally inherited, although paternal mtDNA inheritance was found in a single case with mitochondrial myopathy [@BIB25], [@BIB27], [@BIB9].

The sequence analysis of four complete and 26 partial cheetah mitochondrial genomes identified two SNPs at codon 507 in the *MTND5* and one SNP at position 76 in the *MTND4L* gene. These genes belong to the mitochondrial complex I for which mutations have been reported as one of the most common causes of mitochondrial encephalomyopathies [@BIB7]. One SNP in the *MTND5* consisted of a nonconservative valine to methionine substitution and was found heteroplasmic in 19 cheetahs belonging to haplotype I. The other polymorphic *MTND5* variant leading to the conservative amino acid exchange valine to alanine was found in a homoplasmic state in two cheetahs of haplotype II. In addition, a synonymous homoplasmic polymorphism in the *MTND4L* was demonstrated in the single haplotype III animal. Comparative alignment between different species indicated that the amino acid at codon 507 in the *MTND*5 gene is moderately conserved throughout mammalian evolution, i.e., methionine is encoded by the bovine and alanine by the feline mtDNA (GenBank accession nos. [NC_001567](NC_001567) and [NC_001700](NC_001700)). Nevertheless the nonconservative amino acid exchange valine to methionine probably affects the three-dimensional structure of the resulting ND5 protein, as valine contains only a simple aliphatic side chain, whereas methionine includes a thioether (-S-) group in its side chain. Despite the heteroplasmy was found at high levels (32--79%), only 11 of 19 cheetahs with the mutant genotype had developed myelopathy and statistical analysis did not reveal a significant correlation between the heteroplasmic amino acid exchange and the myelopathy. Pathogenic mutations are usually, but not invariably, heteroplasmic and a minimum critical number of mutant mtDNA molecules must be present before tissue specific dysfunction and clinical signs appear---a concept termed threshold effect [@BIB7]. Homoplasmic exchanges of mtDNA may additionally produce different phenotypes. Interactions between nuclear and mtDNA modify functions of the nervous system, and thus it is suggested that mitochondrial polymorphism in general is probably not as neutral as was previously believed [@BIB23]. The major processes inducing neurodegeneration are considered to be multifactorial [@BIB12] and thus a contribution of mtDNA mutations in the aetiology of the cheetah myelopathy cannot be excluded. A possible mechanism of the aetiopathogenesis could be explained by the oligo-genetic model of nuclear--mitochondrial interaction which involves a primary mitochondrial mutation, not sufficient to induce pathology, and a nuclear modifier contributing to the pathogenic effect of the mtDNA mutation [@BIB5].

Future research should consider a chromosomal genetic cause and the complex nuclear--mitochondrial interactions and investigate whether nuclear modifier genes are involved. The depletion of mtDNA in postmitotic tissue samples can be determined by a PCR-based assay measuring the mtDNA to nuclear DNA ratio [@BIB16]. The spectrophotometrical analysis of mitochondrial enzyme activity [@BIB1] can indicate whether a neurodegenerative disease is related to mitochondria, and thus examinations of mitochondrial enzyme functions should be performed. Extensive viral, bacterial and parasitic examinations without a distinctive indication of association with the cheetah myelopathy were recently published [@BIB31]. Still, future research should consider further pathogenic origins, e.g., the neurotropic strain of coronavirus (JHM-MHV) leading to demyelisation in the CNS of mice [@BIB21] or autoimmune associated causes of demyelisation.

In conclusion, this study reports the complete mtDNA of *A. jubatus* and describes one heteroplasmic and two homoplasmic SNPs in the mitochondrial complex I of cheetahs with and without neurodegenerative disease. Our results showed no significant correlation between the SNPs and the cheetah myelopathy and thus these mutations as singular cause for the neurodegeneration appear unlikely. It remains to be clarified whether the neurodegenerative disease in cheetahs is multifactorial involving a contribution of these mtDNA polymorphisms.
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[^1]: PET: paraffin embedded tissue; not reg.: not registered in the International Studbook 2001; ID: local identification; F1, F2, F3: La Palmyre, Peaugres, Montpellier (France); A1, A2, A3: Salzburg, Herberstein, Vienna (Austria); D: Saarbrücken (Germany); UAE: Dubai (United Arabian Emirates); IRE: Fota (Ireland); NA: not applicable; E: euthanized due to severe symptoms of myelopathy.

[^2]: Blood sample taken 1.5 years before disease onset.

[^3]: Nonconservative.

[^4]: Conservative.

[^5]: \(L\) describes the genes encoded on the L-strand.

[^6]: Signifies an incomplete termination codon.
